FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
· Financial Post
Ingelheim, Germany and Ridgefield, Conn. [DATE] -- The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.1 Read More
Visit asg-reflektory.pl for more information.